An open label trial of cannabidivarin in patients with Rett syndrome
Latest Information Update: 14 May 2019
At a glance
- Drugs Cannabidivarin (Primary)
- Indications Rett syndrome; Seizures
- Focus Therapeutic Use
- 06 May 2019 Status changed from planning to recruiting, according to a GW Pharmaceuticals media release.
- 27 Nov 2018 Planned initiation date changed from 1 Apr 2018 to 1 Jan 2019, according to a GW pharmaceuticals media release.
- 27 Nov 2018 According to a GW pharmaceuticals media release, this trial is due to commence in Q1 2019.